Publicaciones en las que colabora con Carlos Panizo Santos (19)

2023

  1. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

  2. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

    Journal for immunotherapy of cancer, Vol. 11, Núm. 2

2022

  1. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

  2. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

2019

  1. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas

    Blood, Vol. 133, Núm. 22, pp. 2401-2412

  2. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma

    Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

  2. Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in b lymphoid neoplasms

    Haematologica, Vol. 103, Núm. 6, pp. 1065-1072

2017

  1. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study

    European Journal of Haematology, Vol. 98, Núm. 1, pp. 38-43

2016

  1. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

    Nature Communications, Vol. 7

2011

  1. Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma

    Journal of Neuro-Oncology, Vol. 103, Núm. 3, pp. 603-609

2010

  1. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma

    Blood, Vol. 116, Núm. 14, pp. 2531-2542

2006

  1. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

    Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301

2004

  1. Past, present and future of anti-idiotype vaccination

    Revista de medicina de la Universidad de Navarra, Vol. 48, Núm. 3, pp. 14-23

2003

  1. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: Clinical and genetic features of two cases

    Cancer Genetics and Cytogenetics, Vol. 143, Núm. 2, pp. 178-181

1999

  1. Markers of fibrinolytic potency and clotting activation in stable angina pectoris: Role of urokinase, assessment of atrioventricular differences and correlation with coronary patency

    Fibrinolysis and Proteolysis, Vol. 13, Núm. 3, pp. 133-138

1998

  1. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: Implications of germline TP53 mutations

    Medical and Pediatric Oncology, Vol. 30, Núm. 3, pp. 165-169

1994

  1. Indications for bone marrow transplantation

    Revista de medicina de la Universidad de Navarra, Vol. 38, Núm. 4, pp. 212-225